Organon & Co. (NYSE:OGN) Stock Position Boosted by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC boosted its stake in Organon & Co. (NYSE:OGNFree Report) by 23.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 263,051 shares of the company’s stock after buying an additional 50,788 shares during the period. Janney Montgomery Scott LLC owned 0.10% of Organon & Co. worth $4,945,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OGN. Sequoia Financial Advisors LLC bought a new position in shares of Organon & Co. during the 1st quarter valued at about $231,000. Private Advisor Group LLC boosted its holdings in shares of Organon & Co. by 79.6% in the first quarter. Private Advisor Group LLC now owns 25,318 shares of the company’s stock worth $476,000 after buying an additional 11,223 shares during the period. Norden Group LLC acquired a new position in shares of Organon & Co. in the first quarter worth about $355,000. HB Wealth Management LLC acquired a new position in shares of Organon & Co. in the first quarter worth about $218,000. Finally, Perigon Wealth Management LLC acquired a new position in shares of Organon & Co. in the first quarter worth about $193,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 0.1 %

Shares of Organon & Co. stock opened at $19.92 on Thursday. The firm has a market capitalization of $5.12 billion, a PE ratio of 4.87, a price-to-earnings-growth ratio of 0.88 and a beta of 0.85. The company has a debt-to-equity ratio of 181.35, a current ratio of 1.65 and a quick ratio of 1.15. The company’s fifty day moving average price is $20.72 and its two-hundred day moving average price is $18.47. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $24.08.

Organon & Co. (NYSE:OGNGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.31. The business had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 16.50% and a negative return on equity of 360.57%. On average, analysts expect that Organon & Co. will post 4.3 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 13th. Shareholders of record on Monday, May 13th were given a dividend of $0.28 per share. The ex-dividend date was Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a yield of 5.62%. Organon & Co.’s payout ratio is presently 27.38%.

Analysts Set New Price Targets

Several brokerages have commented on OGN. Piper Sandler raised their target price on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, April 29th. The Goldman Sachs Group raised their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd.

View Our Latest Report on Organon & Co.

About Organon & Co.

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

See Also

Want to see what other hedge funds are holding OGN? Visit to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with's FREE daily email newsletter.